Analysts Set Hologic, Inc. (NASDAQ:HOLX) Price Target at $78.75

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have received an average recommendation of "Hold" from the seventeen brokerages that are presently covering the stock, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $78.75.

A number of equities analysts recently issued reports on the company. Evercore ISI upped their price target on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday. Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Royal Bank Of Canada dropped their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Finally, Raymond James Financial restated an "outperform" rating and issued a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd.

Hologic Stock Down 1.7%

NASDAQ HOLX traded down $1.13 on Thursday, hitting $65.72. 1,776,763 shares of the stock were exchanged, compared to its average volume of 2,388,676. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The company has a 50-day moving average price of $61.55 and a 200-day moving average price of $63.54. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The company has a market cap of $14.65 billion, a PE ratio of 27.73, a PEG ratio of 2.45 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the firm posted $1.03 earnings per share. The company's revenue was down 1.2% compared to the same quarter last year. Sell-side analysts anticipate that Hologic will post 4.28 EPS for the current fiscal year.

Insider Activity

In other news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hologic

Large investors have recently modified their holdings of the business. Zions Bancorporation National Association UT acquired a new position in Hologic during the first quarter worth $34,000. Allworth Financial LP boosted its position in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Hologic in the 1st quarter valued at about $42,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.